Sfoglia per Autore
Final results of a phase II randomized trial of neoadjuvant anthracyclinetaxane chemotherapy plus lapatinib, trastuzumab, or both in HER2positive breast cancer (CHERLOB trial)
2011-01-01 Guarneri, ; V, (Guarneri; V., ); Frassoldati; A, (Frassoldati; A., ); Bottini; A, (Bottini; A., ); Generali; Dg, (Generali; D. G., ); Cagossi; K, (Cagossi; K., ); Artioli; F (Artioli, ; F., ); Bisagni; G, (Bisagni; G., ); Boni; C, (Boni; C., ); Ravaioli; A, (Ravaioli; A., ); Amadori; D, (Amadori; D., ).; Musolino, A; Cavanna, ; L, (Cavanna; L., ); Untch; M, (Untch; M., ); Orlando; L, (Orlando; L., ); Giardina; G, (Giardina; G., ); Piacentini; F, (Piacentini; F., ); Tagliafico; E, (Tagliafico; E., ); Bagnalasta; M, (Bagnalasta; M., ); D'Amico; R, (D'Amico; R., ); Conte; Pf, (Conte; P. F., ).
TransCHERLob: A Biomarker Analysis of the Randomized Phase II Study of Neoadjuvant Chemotherapy Plus Trastuzumab, Lapatinib or Combined Trastuzumab and Lapatinib in HER2 Positive Operable Breast Cancer
2011-01-01 Guarneri, ; V, (Guarneri; V., ); Frassoldati; A, (Frassoldati; A., ); Ficarra; G, (Ficarra; G., ); Maiorana; A, (Maiorana; A., ); Bettelli; S, (Bettelli; S., ); Bottini; A, (Bottini; A., ); Cagossi; K, (Cagossi; K., ); Bisagni; G, (Bisagni; G., ); Ravaioli; A, (Ravaioli; A., ); Amadori; D, (Amadori; D., ).; Musolino, A; Cavanna, ; L, (Cavanna; L., ); Orlando; L, (Orlando; L., ); Giardina; G, (Giardina; G., ); Piacentini; F, (Piacentini; F., ); Bagnalasta; M, (Bagnalasta; M., ); Conte; P, (Conte; P., ).
Activity and Safety of DoseAdjusted Infusional Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Chemotherapy With Rituximab in Very Elderly Patients With PoorPrognostic Untreated Diffuse Large B Cell Non Hodgkin Lymphoma
2011-01-01 Musolino, A; Boggiani, ; D, (Boggiani; Daniela);, Panebianco; M, (Panebianco; Michele);, Vasini; G, (Vasini; Giovanna);, Salvagni; S (Salvagni, ; Stefania);, Franciosi; V, (Franciosi; Vittorio);, Ardizzoni; A, (Ardizzoni; Andrea),
Human epidermal growth factor receptor 2 status and interval breast cancer in a population-based cancer registry study
2012-01-01 Musolino, A.; Michiara, M.; Conti, G. M.; Boggiani, D.; Zatelli, M.; Palleschi, D.; Bella, M. A.; Sgargi, P.; Di Blasio, B.; Ardizzoni, A.
BRCA STATUS, MOLECULAR PROFILE AND CLINICAL VARIABLES IN PRIMARY BILATERAL BREAST CANCERS: A POPULATION-BASED CANCER REGISTRY STUDY
2012-01-01 Musolino, A; Bella, Ma; Michiara, M; Zanelli, P; Naldi, N; Bortesi, B; Sgargi, P; Camisa, R; Neri, Tm; Ardizzoni, A
Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: Results of the randomized phase II CHER-LOB study
2012-01-01 Guarneri, V.; Frassoldati, A.; Bottini, A.; Cagossi, K.; Bisagni, G.; Sarti, S.; Ravaioli, A.; Cavanna, L.; Giardina, G.; Musolino, A.; Untch, M.; Orlando, L.; Artioli, F.; Boni, C.; Generali, D. G.; Serra, P.; Bagnalasta, M.; Marini, L.; Piacentini, F.; D'Amico, R.; Conte, P.
Notch and DLL4 expression in bevacizumab treated colon cancer patients
2013-01-01 Negri, ; F, (Negri; Francesca);, Bozzetti; C, (Bozzetti; Cecilia);, Crafa; P, (Crafa; Pellegrino);, Lagrasta; C, (Lagrasta; Costanza);, Cavalli; S, (Cavalli; Stefano); Pedrazzi, ; G, (Pedrazzi; Giuseppe);, Gardini; G, (Gardini; Giorgio);, Tamagnini; I, (Tamagnini; Ione);, Porzio; R, (Porzio; Rosa);, Cavanna; L, (Cavanna; Luigi);, Paties; C (Paties, ; Carlo);, Romano; I, (Romano; Ida), ; Musolino, A; Tomasello, ; G, (Tomasello; Gianluca);, Petronini; Pg, (Petronini; Pier Giorgio);, Ardizzoni; A (Ardizzoni, ; Andrea),
The Breast Avastin Trial: Phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer
2013-01-01 Bisagni, G.; Musolino, A.; Panebianco, M.; De Matteis, A.; Nuzzo, F.; Ardizzoni, A.; Gori, S.; Gamucci, T.; Passalacqua, R.; Gnoni, R.; Moretti, G.; Boni, C.
Risk of breast cancer in ovarian cancer patients non-carriers of BRCA1 and BRCA2 mutations with a family history of breast and ovarian cancer: A population-based cancer registry study
2013-01-01 Musolino, A; Boggiani, D; Bella, Ma; Zanelli, P; Naldi, N; Bortesi, B; Sgargi, P; Michiara, M; Ardizzoni, A
Dovitinib plus fulvestrant in postmenopausal endocrine resistant HER2-/ HR+ breast cancer: A phase II, randomized, placebo-controlled study
2013-01-01 Andre, F; Neven, P; Musolino, A; Latini, L; Campone, M; Cortes, J; Barrios, Ch; Squires, M; Zhang, Y; Deudon, S; Yovine, Aj; Blackwell, Kl
BOLERO-3 results: Pharmacological activity or pharmacokinetic effect?
2014-01-01 Buti, S.; Bersanelli, M.; Tiseo, M.; Ardizzoni, A.; Musolino, A.
Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy
2014-01-01 Negri, F. V.; Musolino, A.; Naldi, N.; Bortesi, B.; Missale, G.; Laccabue, D.; Zerbini, A.; Camisa, R.; Chernyschova, N.; Bisagni, G.; Loupakis, F.; Ruzzo, A.; Neri, T. M.; Ardizzoni, A.
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in patients with HER2positive operable breast cancer
2015-01-01 Musolino, A; Guarneri V; Naldi N; Bortesi B; Boggiani D; Sgargi P; Generali DG; Piacentini F; Dieci MV; Ambroggi M; Cagossi K; Gianni L; Sarti S; Bisagni G; Frassoldati A; Conte P; Ardizzoni, A
Prognostic impact of HER2 overexpression/amplification in women with pT1a N0 M0 breast cancer with known screening status: First results from a multicenter population based cancer registry study
2015-01-01 Musolino, A; Michiara M; Boggiani D; Sikokis A; Rimanti A; Pellegrino B; Martella E; Bozzani F; Sgargi P; Panebianco M; Bisagni G; Falcini F; Pinto, C
Family history for BRCA1 and BRCA2 mutations in patients with pancreatic cancer: An observational, population based study
2015-01-01 Boggiani D; Bella M; Zanelli P; Michiara M; Mazzaschi, G; Musolino, A; Naldi N; Bortesi B; Cortesi L; Pinto, C
Results from the phase 2 trial of ridaforolimus, dalotuzumab, and exemestane compared to ridaforolimus and exemestane in advanced breast cancer
2015-01-01 Rugo, ; Hs, (Rugo; Hope S., ); Tredan; O, (Tredan; Olivier);, Ro; J, (Ro; Jungsil);, Morales; S, (Morales; Serafin), ; Musolino, A; Afonso, ; N, (Afonso; Noemia);, Ferreira; M, (Ferreira; Marta);, Park; Kh, (Park; Kyong Hwa);, Cortes; J, (Cortes; Javier);, Tan; Ar, (Tan; Antoinette R., ); Blum; Jl, (Blum; Joanne L., ); Eaton; L, (Eaton; Lamar);, Gause; Ck, (Gause; Christine K., ); Wang; A, (Wang; Adelle (Zhen));, Im; E, (Im; Ellie);, Mauro; Dj, (Mauro; David J., ); Baselga; J, (Baselga; Jose),
Italian observational study of Eribulin Mesylate in patients with advanced breast cancer: ESEMPiO study
2015-01-01 Barni S; Fontanella C; Del Mastro L; Livraghi L; Morritti M; Pizzuti L; Michelotti A; Lutrino ES; Ciccarese, M; Musolino, A; Quercia S; Garrone O; Pellegrino A; Pistelli M; Martella F; Iezzi L; Mentuccia L; Latorre A; D'Onofrio L; Porcu, L
Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer
2015-01-01 Guarneri, V.; Dieci, M. V.; Frassoldati, A.; Maiorana, A.; Ficarra, G.; Bettelli, S.; Tagliafico, E.; Bicciato, S.; Generali, D. G.; Cagossi, K.; Bisagni, G.; Sarti, S.; Musolino, A.; Ellis, C.; Crescenzo, R.; Conte, P.
Prognostic impact of interval breast cancer detection in women with pT1aN0M0 breast cancer with HER2-positive status: Results from a Multicenter Population-based Cancer Registry Study
2016-01-01 Boggiani, D; Sikokis, A; Rimanti, A; Pellegrino, B; Silini, Em; Campanini, N; Barbieri, E; Cortesi, L; Panebianco, M; Porzio, R; Frassoldati, A; Sgargi, P; Falcini, F; Michiara, M; Musolino, A
Prognostic impact of HER2 overexpression/amplification in women with pT1a NO MO breast cancer with known screening status: Results from a multicenter populationbased cancer registry study
2016-01-01 Musolino, A; Michiara M; Boggiani D; Sikokis A; Rimanti A; Pellegrino B; Silini EM; Campanini N; Barbieri E; Sgargi P; Falcini F; Pinto, C
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Final results of a phase II randomized trial of neoadjuvant anthracyclinetaxane chemotherapy plus lapatinib, trastuzumab, or both in HER2positive breast cancer (CHERLOB trial) | 1-gen-2011 | Guarneri, ; V, (Guarneri; V., ); Frassoldati; A, (Frassoldati; A., ); Bottini; A, (Bottini; A., ); Generali; Dg, (Generali; D. G., ); Cagossi; K, (Cagossi; K., ); Artioli; F (Artioli, ; F., ); Bisagni; G, (Bisagni; G., ); Boni; C, (Boni; C., ); Ravaioli; A, (Ravaioli; A., ); Amadori; D, (Amadori; D., ).; Musolino, A; Cavanna, ; L, (Cavanna; L., ); Untch; M, (Untch; M., ); Orlando; L, (Orlando; L., ); Giardina; G, (Giardina; G., ); Piacentini; F, (Piacentini; F., ); Tagliafico; E, (Tagliafico; E., ); Bagnalasta; M, (Bagnalasta; M., ); D'Amico; R, (D'Amico; R., ); Conte; Pf, (Conte; P. F., ). | |
| TransCHERLob: A Biomarker Analysis of the Randomized Phase II Study of Neoadjuvant Chemotherapy Plus Trastuzumab, Lapatinib or Combined Trastuzumab and Lapatinib in HER2 Positive Operable Breast Cancer | 1-gen-2011 | Guarneri, ; V, (Guarneri; V., ); Frassoldati; A, (Frassoldati; A., ); Ficarra; G, (Ficarra; G., ); Maiorana; A, (Maiorana; A., ); Bettelli; S, (Bettelli; S., ); Bottini; A, (Bottini; A., ); Cagossi; K, (Cagossi; K., ); Bisagni; G, (Bisagni; G., ); Ravaioli; A, (Ravaioli; A., ); Amadori; D, (Amadori; D., ).; Musolino, A; Cavanna, ; L, (Cavanna; L., ); Orlando; L, (Orlando; L., ); Giardina; G, (Giardina; G., ); Piacentini; F, (Piacentini; F., ); Bagnalasta; M, (Bagnalasta; M., ); Conte; P, (Conte; P., ). | |
| Activity and Safety of DoseAdjusted Infusional Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Chemotherapy With Rituximab in Very Elderly Patients With PoorPrognostic Untreated Diffuse Large B Cell Non Hodgkin Lymphoma | 1-gen-2011 | Musolino, A; Boggiani, ; D, (Boggiani; Daniela);, Panebianco; M, (Panebianco; Michele);, Vasini; G, (Vasini; Giovanna);, Salvagni; S (Salvagni, ; Stefania);, Franciosi; V, (Franciosi; Vittorio);, Ardizzoni; A, (Ardizzoni; Andrea), | |
| Human epidermal growth factor receptor 2 status and interval breast cancer in a population-based cancer registry study | 1-gen-2012 | Musolino, A.; Michiara, M.; Conti, G. M.; Boggiani, D.; Zatelli, M.; Palleschi, D.; Bella, M. A.; Sgargi, P.; Di Blasio, B.; Ardizzoni, A. | |
| BRCA STATUS, MOLECULAR PROFILE AND CLINICAL VARIABLES IN PRIMARY BILATERAL BREAST CANCERS: A POPULATION-BASED CANCER REGISTRY STUDY | 1-gen-2012 | Musolino, A; Bella, Ma; Michiara, M; Zanelli, P; Naldi, N; Bortesi, B; Sgargi, P; Camisa, R; Neri, Tm; Ardizzoni, A | |
| Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: Results of the randomized phase II CHER-LOB study | 1-gen-2012 | Guarneri, V.; Frassoldati, A.; Bottini, A.; Cagossi, K.; Bisagni, G.; Sarti, S.; Ravaioli, A.; Cavanna, L.; Giardina, G.; Musolino, A.; Untch, M.; Orlando, L.; Artioli, F.; Boni, C.; Generali, D. G.; Serra, P.; Bagnalasta, M.; Marini, L.; Piacentini, F.; D'Amico, R.; Conte, P. | |
| Notch and DLL4 expression in bevacizumab treated colon cancer patients | 1-gen-2013 | Negri, ; F, (Negri; Francesca);, Bozzetti; C, (Bozzetti; Cecilia);, Crafa; P, (Crafa; Pellegrino);, Lagrasta; C, (Lagrasta; Costanza);, Cavalli; S, (Cavalli; Stefano); Pedrazzi, ; G, (Pedrazzi; Giuseppe);, Gardini; G, (Gardini; Giorgio);, Tamagnini; I, (Tamagnini; Ione);, Porzio; R, (Porzio; Rosa);, Cavanna; L, (Cavanna; Luigi);, Paties; C (Paties, ; Carlo);, Romano; I, (Romano; Ida), ; Musolino, A; Tomasello, ; G, (Tomasello; Gianluca);, Petronini; Pg, (Petronini; Pier Giorgio);, Ardizzoni; A (Ardizzoni, ; Andrea), | |
| The Breast Avastin Trial: Phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer | 1-gen-2013 | Bisagni, G.; Musolino, A.; Panebianco, M.; De Matteis, A.; Nuzzo, F.; Ardizzoni, A.; Gori, S.; Gamucci, T.; Passalacqua, R.; Gnoni, R.; Moretti, G.; Boni, C. | |
| Risk of breast cancer in ovarian cancer patients non-carriers of BRCA1 and BRCA2 mutations with a family history of breast and ovarian cancer: A population-based cancer registry study | 1-gen-2013 | Musolino, A; Boggiani, D; Bella, Ma; Zanelli, P; Naldi, N; Bortesi, B; Sgargi, P; Michiara, M; Ardizzoni, A | |
| Dovitinib plus fulvestrant in postmenopausal endocrine resistant HER2-/ HR+ breast cancer: A phase II, randomized, placebo-controlled study | 1-gen-2013 | Andre, F; Neven, P; Musolino, A; Latini, L; Campone, M; Cortes, J; Barrios, Ch; Squires, M; Zhang, Y; Deudon, S; Yovine, Aj; Blackwell, Kl | |
| BOLERO-3 results: Pharmacological activity or pharmacokinetic effect? | 1-gen-2014 | Buti, S.; Bersanelli, M.; Tiseo, M.; Ardizzoni, A.; Musolino, A. | |
| Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy | 1-gen-2014 | Negri, F. V.; Musolino, A.; Naldi, N.; Bortesi, B.; Missale, G.; Laccabue, D.; Zerbini, A.; Camisa, R.; Chernyschova, N.; Bisagni, G.; Loupakis, F.; Ruzzo, A.; Neri, T. M.; Ardizzoni, A. | |
| Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in patients with HER2positive operable breast cancer | 1-gen-2015 | Musolino, A; Guarneri V; Naldi N; Bortesi B; Boggiani D; Sgargi P; Generali DG; Piacentini F; Dieci MV; Ambroggi M; Cagossi K; Gianni L; Sarti S; Bisagni G; Frassoldati A; Conte P; Ardizzoni, A | |
| Prognostic impact of HER2 overexpression/amplification in women with pT1a N0 M0 breast cancer with known screening status: First results from a multicenter population based cancer registry study | 1-gen-2015 | Musolino, A; Michiara M; Boggiani D; Sikokis A; Rimanti A; Pellegrino B; Martella E; Bozzani F; Sgargi P; Panebianco M; Bisagni G; Falcini F; Pinto, C | |
| Family history for BRCA1 and BRCA2 mutations in patients with pancreatic cancer: An observational, population based study | 1-gen-2015 | Boggiani D; Bella M; Zanelli P; Michiara M; Mazzaschi, G; Musolino, A; Naldi N; Bortesi B; Cortesi L; Pinto, C | |
| Results from the phase 2 trial of ridaforolimus, dalotuzumab, and exemestane compared to ridaforolimus and exemestane in advanced breast cancer | 1-gen-2015 | Rugo, ; Hs, (Rugo; Hope S., ); Tredan; O, (Tredan; Olivier);, Ro; J, (Ro; Jungsil);, Morales; S, (Morales; Serafin), ; Musolino, A; Afonso, ; N, (Afonso; Noemia);, Ferreira; M, (Ferreira; Marta);, Park; Kh, (Park; Kyong Hwa);, Cortes; J, (Cortes; Javier);, Tan; Ar, (Tan; Antoinette R., ); Blum; Jl, (Blum; Joanne L., ); Eaton; L, (Eaton; Lamar);, Gause; Ck, (Gause; Christine K., ); Wang; A, (Wang; Adelle (Zhen));, Im; E, (Im; Ellie);, Mauro; Dj, (Mauro; David J., ); Baselga; J, (Baselga; Jose), | |
| Italian observational study of Eribulin Mesylate in patients with advanced breast cancer: ESEMPiO study | 1-gen-2015 | Barni S; Fontanella C; Del Mastro L; Livraghi L; Morritti M; Pizzuti L; Michelotti A; Lutrino ES; Ciccarese, M; Musolino, A; Quercia S; Garrone O; Pellegrino A; Pistelli M; Martella F; Iezzi L; Mentuccia L; Latorre A; D'Onofrio L; Porcu, L | |
| Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer | 1-gen-2015 | Guarneri, V.; Dieci, M. V.; Frassoldati, A.; Maiorana, A.; Ficarra, G.; Bettelli, S.; Tagliafico, E.; Bicciato, S.; Generali, D. G.; Cagossi, K.; Bisagni, G.; Sarti, S.; Musolino, A.; Ellis, C.; Crescenzo, R.; Conte, P. | |
| Prognostic impact of interval breast cancer detection in women with pT1aN0M0 breast cancer with HER2-positive status: Results from a Multicenter Population-based Cancer Registry Study | 1-gen-2016 | Boggiani, D; Sikokis, A; Rimanti, A; Pellegrino, B; Silini, Em; Campanini, N; Barbieri, E; Cortesi, L; Panebianco, M; Porzio, R; Frassoldati, A; Sgargi, P; Falcini, F; Michiara, M; Musolino, A | |
| Prognostic impact of HER2 overexpression/amplification in women with pT1a NO MO breast cancer with known screening status: Results from a multicenter populationbased cancer registry study | 1-gen-2016 | Musolino, A; Michiara M; Boggiani D; Sikokis A; Rimanti A; Pellegrino B; Silini EM; Campanini N; Barbieri E; Sgargi P; Falcini F; Pinto, C |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile